Antares secured a major discovery and commercialization collaboration with Novartis aimed at small-molecule oncology targets considered historically undruggable. The Cambridge, Massachusetts-based company will receive $105 million upfront and can earn up to $1.8 billion in milestone payments, plus tiered royalties tied to global net sales. Under the agreement, Antares will lead discovery and apply its covalent drug discovery engine—built around screening libraries, chemical proteomics, structure-driven computational chemistry, and machine-learning—to generate program candidates until Novartis exercises options on individual targets. The pact signals continued pharma interest in platform-driven approaches to expand oncology targetable space, while also supporting Antares’ independent pipeline development in parallel. Novartis biomedical research leadership said the company is expanding its attempt to reach new oncology frontiers. For biotech investors, the scale of the upfront and milestone structure underscores how large-cap partners are still paying for early target-to-lead capability when it comes with a clear platform and disciplined program ownership.